{"id":"nitracrine","rwe":[],"tags":[{"label":"nitracrine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Nucleic Acid Synthesis Inhibitors","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ledakrin","offLabel":[],"synonyms":["ledakrin","C-283","C283","nitracrine"],"timeline":[],"approvals":[],"brandName":"Ledakrin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nitracrine","explanation":"Imagine Ledakrin as a key that fits into a lock in the body. When it binds to its target, it can help to regulate various cellular processes, but the exact way it does this is still a mystery. More research is needed to fully understand how Ledakrin works and what effects it may have on the body.","oneSentence":"Ledakrin works by binding to a specific target in the body, although the exact nature of this interaction is not well understood.","technicalDetail":"As a nitracrine, Ledakrin is a type of small molecule that interacts with a specific target, likely a nuclear receptor or other protein, to produce its effects. The exact mechanism of action is not well-documented, but it is thought to involve the modulation of gene expression or other downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3386","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITRACRINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:59:15.697687","biosimilars":[],"competitors":[],"genericName":"nitracrine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"712MLZ30SB","CHEBI":"CHEBI:135384","INN_ID":"3916","UMLSCUI":"C0028120","ChEMBL_ID":"CHEMBL26291","PUBCHEM_CID":"20628","MESH_DESCRIPTOR_UI":"D009564"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":67,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ledakrin (NITRACRINE) is a small molecule nitracrine drug with an unknown target. Its mechanism of action is not well-documented, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the potential benefits and risks of this compound. Due to the lack of available data, it is difficult to provide a comprehensive summary of Ledakrin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}